Overview

To Evaluate KC1036 in the Patients With Advanced Digestive System Tumors

Status:
Not yet recruiting
Trial end date:
2025-04-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the preliminary efficacy, safety, tolerability and pharmacokinetics of KC1036 in participants with advanced recurrent or metastatic digestive system tumors.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Beijing Konruns Pharmaceutical Co., Ltd.